FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080931115> ?p ?o ?g. }

• W2080931115 endingPage "1243" @default.
• W2080931115 startingPage "1232" @default.
• W2080931115 abstract "Abstract Purpose: To evaluate the safety, pharmacokinetics, and pharmacodynamics of BAY 86-9766, a selective, potent, orally available, small-molecule allosteric inhibitor of mitogen-activated protein kinase 1/2 in patients with advanced solid tumors. Experimental Design: BAY 86-9766 was administered orally daily in 28-day courses, with doses escalated to establish the maximum-tolerated dose (MTD). An expanded cohort was evaluated at the MTD. Pharmacokinetic and pharmacodynamic parameters were assessed, with extracellular signal–regulated kinase (ERK) phosphorylation evaluated in paired biopsies from a subset of the expanded MTD cohort. Tumor specimens were evaluated for mutations in select genes. Results: Sixty-nine patients were enrolled, including 20 patients at the MTD. The MTD was 100 mg given once-daily or in two divided doses. BAY 86-9766 was well-tolerated. The most common treatment-related toxicities were acneiform rash and gastrointestinal toxicity. BAY 86-9766 was well-absorbed after oral administration (plasma half-life ∼12 hours), and displayed dose proportional pharmacokinetics throughout the tested dose range. Continuous daily dosing resulted in moderate accumulation at most dose levels. BAY 86-9766 suppressed ERK phosphorylation in biopsied tissue and tetradecanoylphorbol acetate–stimulated peripheral blood leukocytes. Of 53 evaluable patients, one patient with colorectal cancer achieved a partial response and 11 patients had stable disease for 4 or more courses. An ocular melanoma specimen harbored a GNAQ-activating mutation and exhibited reduced ERK phosphorylation in response to therapy. Conclusion: This phase I study showed that BAY 86-9766 was well-tolerated, with good oral absorption, dose proportional pharmacokinetics, target inhibition at the MTD, and some evidence of clinical benefit across a range of tumor types. Clin Cancer Res; 19(5); 1232–43. ©2012 AACR." @default.
• W2080931115 created "2016-06-24" @default.
• W2080931115 creator A5003463083 @default.
• W2080931115 creator A5003967456 @default.
• W2080931115 creator A5006718606 @default.
• W2080931115 creator A5010628808 @default.
• W2080931115 creator A5016696675 @default.
• W2080931115 creator A5025646273 @default.
• W2080931115 creator A5026482426 @default.
• W2080931115 creator A5032410510 @default.
• W2080931115 creator A5035201571 @default.
• W2080931115 creator A5037169725 @default.
• W2080931115 creator A5041114807 @default.
• W2080931115 creator A5050452018 @default.
• W2080931115 creator A5051676242 @default.
• W2080931115 creator A5068231843 @default.
• W2080931115 creator A5074686012 @default.
• W2080931115 creator A5080669646 @default.
• W2080931115 creator A5080900202 @default.
• W2080931115 creator A5081014851 @default.
• W2080931115 creator A5082147062 @default.
• W2080931115 creator A5089927948 @default.
• W2080931115 date "2013-03-01" @default.
• W2080931115 modified "2023-09-23" @default.
• W2080931115 title "Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer" @default.
• W2080931115 cites W1971380103 @default.
• W2080931115 cites W1971947883 @default.
• W2080931115 cites W1974091059 @default.
• W2080931115 cites W1988379285 @default.
• W2080931115 cites W2011826559 @default.
• W2080931115 cites W2036614475 @default.
• W2080931115 cites W2050422354 @default.
• W2080931115 cites W2066393891 @default.
• W2080931115 cites W2070686081 @default.
• W2080931115 cites W2080686146 @default.
• W2080931115 cites W2096046981 @default.
• W2080931115 cites W2108517627 @default.
• W2080931115 cites W2114502358 @default.
• W2080931115 cites W2120203403 @default.
• W2080931115 cites W2129370444 @default.
• W2080931115 cites W2129400742 @default.
• W2080931115 cites W2129429534 @default.
• W2080931115 cites W2130979878 @default.
• W2080931115 cites W2134758896 @default.
• W2080931115 cites W2136656327 @default.
• W2080931115 cites W2137990944 @default.
• W2080931115 cites W2139248078 @default.
• W2080931115 cites W2150772498 @default.
• W2080931115 cites W2156509877 @default.
• W2080931115 cites W2157232767 @default.
• W2080931115 cites W2163188200 @default.
• W2080931115 cites W2246017419 @default.
• W2080931115 cites W3021431521 @default.
• W2080931115 doi "https://doi.org/10.1158/1078-0432.ccr-12-3529" @default.
• W2080931115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23434733" @default.
• W2080931115 hasPublicationYear "2013" @default.
• W2080931115 type Work @default.
• W2080931115 sameAs 2080931115 @default.
• W2080931115 citedByCount "54" @default.
• W2080931115 countsByYear W20809311152013 @default.
• W2080931115 countsByYear W20809311152014 @default.
• W2080931115 countsByYear W20809311152015 @default.
• W2080931115 countsByYear W20809311152016 @default.
• W2080931115 countsByYear W20809311152017 @default.
• W2080931115 countsByYear W20809311152018 @default.
• W2080931115 countsByYear W20809311152019 @default.
• W2080931115 countsByYear W20809311152020 @default.
• W2080931115 countsByYear W20809311152021 @default.
• W2080931115 countsByYear W20809311152022 @default.
• W2080931115 countsByYear W20809311152023 @default.
• W2080931115 crossrefType "journal-article" @default.
• W2080931115 hasAuthorship W2080931115A5003463083 @default.
• W2080931115 hasAuthorship W2080931115A5003967456 @default.
• W2080931115 hasAuthorship W2080931115A5006718606 @default.
• W2080931115 hasAuthorship W2080931115A5010628808 @default.
• W2080931115 hasAuthorship W2080931115A5016696675 @default.
• W2080931115 hasAuthorship W2080931115A5025646273 @default.
• W2080931115 hasAuthorship W2080931115A5026482426 @default.
• W2080931115 hasAuthorship W2080931115A5032410510 @default.
• W2080931115 hasAuthorship W2080931115A5035201571 @default.
• W2080931115 hasAuthorship W2080931115A5037169725 @default.
• W2080931115 hasAuthorship W2080931115A5041114807 @default.
• W2080931115 hasAuthorship W2080931115A5050452018 @default.
• W2080931115 hasAuthorship W2080931115A5051676242 @default.
• W2080931115 hasAuthorship W2080931115A5068231843 @default.
• W2080931115 hasAuthorship W2080931115A5074686012 @default.
• W2080931115 hasAuthorship W2080931115A5080669646 @default.
• W2080931115 hasAuthorship W2080931115A5080900202 @default.
• W2080931115 hasAuthorship W2080931115A5081014851 @default.
• W2080931115 hasAuthorship W2080931115A5082147062 @default.
• W2080931115 hasAuthorship W2080931115A5089927948 @default.
• W2080931115 hasBestOaLocation W20809311151 @default.
• W2080931115 hasConcept C111113717 @default.
• W2080931115 hasConcept C112705442 @default.
• W2080931115 hasConcept C121608353 @default.
• W2080931115 hasConcept C126322002 @default.
• W2080931115 hasConcept C184235292 @default.
• W2080931115 hasConcept C2781249067 @default.

• next